Search for European Projects

11 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)

Start date: May 1, 2015, End date: Apr 30, 2020,

... moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parki ...
Read Project

 17

 FINISHED 

DC-based immunotherapy to treat Malignant Mesothelioma (H2020MM04)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millio ...
Read Project

 8

 FINISHED 

DIabetes REsearCh on patient sTratification (DIRECT)

Start date: Feb 1, 2012, End date: Jan 31, 2019,

The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Read Project

 27

 FINISHED 

"Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance" (MON4STRAT)

Start date: Feb 1, 2014, End date: Jan 31, 2018,

...cable dose adjustments during treatment and thus (iii) to improve efficacy while reducing risk of EDR or adverse effects.The MON4STRAT approach will be validated through a prospective, multicentre, randomized clinical trial with150 adults. Its applicability in paediatrics will be tested through an observational study with 70 children/neonates.Being generic in nature, MON4STRAT will be replicable t ...
Read Project

 13

 FINISHED 

European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Read Project

 38

 FINISHED 

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease (NILVAD)

Start date: Jan 1, 2012, End date: Dec 31, 2016,

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Read Project

 17

 FINISHED 

Development of biophotonic device based on flexible light emitting textile dedicated to the monitoring and treatment for dermatologic diseases and carcinoma (PHOS-ISTOS)

Start date: Dec 1, 2013, End date: Nov 30, 2016,

The therapeutic effect of the photodynamic therapy (PDT) depends on a combination of parameters that include drug dose, drug-light interval, oxygen in cells and light irradiance rate. It also varies according to the wavelength distribution of the light source. Finally, a homogeneous and reproducible illumination during the clinical PDT is determinant in preventing under- or overtreatment. So, the ...
Read Project

 12

 FINISHED 

Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise (PEVNET)

Start date: Jan 1, 2011, End date: Jun 30, 2016,

"Type 1 diabetes is caused by an inflammatory process which damage insulin-producing beta-cells in the pancreas. It is one of the most common chronic diseases and its incidence is rapidly increasing. Due to its complications it causes a significant medical and economic burden to European society. A causal association between enterovirus and type 1 diabetes has become more and more likely. The aim ...
Read Project

 14

 FINISHED 

Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)

Start date: Nov 1, 2008, End date: Apr 30, 2012,

"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Read Project

 12

 FINISHED 

Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)

Start date: Feb 1, 2009, End date: Mar 31, 2012,

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Read Project

 19

 FINISHED 

PATIENT SAFETY THROUGH INTELLIGENT PROCEDURES IN MEDICATION (PSIP)

Start date: Jan 1, 2008, End date: Jul 31, 2011,

Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. They endanger the patients' safety and originate considerable extra hospital costs.Healthcare ICT applications should help reducing the prevalence of preventable ADE, by providing healthcare professionals and patients with relevant knowledge (guidelines, recomm ...
Read Project

 13